Applied Genetic Technologies Corporation Stock Company Profile

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.